Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center
Ohio State University Comprehensive Cancer Center
Eisai Inc.
BeiGene
City of Hope Medical Center
Columbia University
Pfizer
Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd.
Northwestern University
Stanford University
National Institutes of Health Clinical Center (CC)
University of Nebraska
University of Nebraska
University of Nebraska
Columbia University
OncoSec Medical Incorporated
Stanford University
Atara Biotherapeutics
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc
Ludwig Institute for Cancer Research
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
Soligenix
miRagen Therapeutics, Inc.
Alexion Pharmaceuticals, Inc.
Rochester Skin Lymphoma Medical Group, PLLC
Novartis
Roswell Park Cancer Institute
Eisai Inc.
Galderma R&D
Fred Hutchinson Cancer Center
Takeda
M.D. Anderson Cancer Center
Eli Lilly and Company
M.D. Anderson Cancer Center
Roswell Park Cancer Institute
Jonsson Comprehensive Cancer Center
Mayo Clinic
Helsinn Therapeutics (U.S.), Inc
Fred Hutchinson Cancer Center
Rhizen Pharmaceuticals SA
Roswell Park Cancer Institute
Bausch Health Americas, Inc.
Celgene
Roswell Park Cancer Institute
Northwestern University